Search Results

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise

Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.

https://www.seqirus.com/manufacturing/global-manufacturing-network

Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.

https://www.seqirus.com/manufacturing/technologies

Seqirus – a global leader in influenza prevention and a business of CSL Limited - has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute.

https://www.seqirus.com/news/csls-seqirus-and-the-university-of-liverpool-pandemic-institute-launch-collaboration

Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.

https://www.seqirus.com/our-company/leadership

Seqirus is working tirelessly to optimise our technology and implement transformational long-term approaches to influenza pandemic preparedness.

https://www.seqirus.com/r-and-d

Understand our aim to develop the next generation of influenza vaccines and how we're working to unite product platforms across the globe.

https://www.seqirus.com/manufacturing/technical-development

Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.

https://www.seqirus.com/

Collaborating to improve patient outcomes in Myanmar.

https://www.seqirus.com/expertise/antivenom-and-q-fever-vaccines/case-study-myanmar

Seqirus is the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more about our pharmaceutical partnership capabilities.

https://www.seqirus.com/expertise/in-licensing